NCT00270413已完成2 期
A Belgian Multicenter Phase II Randomized Trial in her2 Negative Metastatic Breast Cancer Evaluating Consolidation Antiangiogenic Therapy With SU11248 After Response to Taxane Chemotherapy Induction
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 19
- 试验地点
- 13
- 主要终点
- Progression Free Survival (PFS) at 5 months (= proportion of patients alive and free of progression 5 months after starting therapy in the sunitinib arm (control arm = only for descriptive purpose)
研究概览
简要总结
This study tests the hypothesis that SU11248 can delay tumor progression after tumor mass reduction by taxanes. This is a dual-arm open-label randomized multicenter phase II clinical trial with 2:1 randomization evaluating the efficacy of SU11248 versus nil in patients with metastatic breast cancer after objective response to taxane chemotherapy. Patients randomized to the placebo arm (Arm B) will be offered the opportunity to receive open-label SU011248 treatment upon development of Response Evaluation Criteria in Solid Tumors (RECIST)-defined disease progression.
详细描述
This study tests the hypothesis that SU11248 can delay tumor progression after tumor mass reduction by taxanes. This is a dual-arm open-label randomized multicenter phase II clinical trial with 2:1 randomization evaluating the efficacy of SU11248 versus nil in patients with metastatic breast cancer after objective response to taxane chemotherapy. Patients randomized to the placebo arm (Arm B) will be offered the opportunity to receive open-label SU011248 treatment upon development of RECIST-defined disease progression
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients with metastatic breast cancer, histologically proven
- •Patients received taxane based chemotherapy resulting in PR or CR, and thus had measurable disease at the start of taxane therapy (RECIST)
- •No more than 2 lines (taxanes included) in metastatic setting
- •Patients have received at least 10 weeks of taxane therapy (4 cycles of 3-weekly therapy or 8 weekly administrations) and no more than 20 weeks of treatment (6 cycles of 3-weekly therapy or 16 weekly administrations). 6 cycles of 3-weekly taxanes or 12-16 cycles of weekly taxanes are recommended.
- •Last taxane administration between 3 and 4 weeks for 3 weekly taxane or between 2 and 3 weeks for weekly taxanes
- •Performance status 0 to 1 on the ECOG scale (Appendix A)
- •Age > 18 years
- •Adequate organ function as defined by:
- •Serum aspartate aminotransferase (AST; serum glutamate-oxalate transferase [SGOT]) and serum alanine aminotransferase (ALT; serum glutamate-pyruvate transferase [SGPT]) ≤2.5 x central laboratory upper limit of normal (CL-ULN). If liver function abnormalities are due to underlying malignancy, then AST and ALT may be ≤5 x CL-ULN
- •Prothrombin time (PT) > 50%
- •Serum albumin ≥3.0 g/dL
- •Absolute neutrophil count (ANC) ≥1500/µL
- •Platelets ≥100,000/µL
- •Hemoglobin ≥9.0 g/dL
- •Serum creatinine ≤1.5 x CL-ULN
- •Serum amylase and lipase ≤1.0 x CL-ULN
- •Left ventricular ejection fraction (LVEF) above the lower limit of normal (LLN) as assessed by multigated acquisition (MUGA) scan or echocardiography.
- •Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
- •Before patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations.
排除标准
- •Her2 neu positive tumor with IHC 3+ or FISH+
- •Concurrent hormone therapy (tamoxifen, aromatase inhibitors, other hormone suppressing therapies) with SU
- •Concurrent treatment with hormonal replacement therapy
- •Concurrent treatment with any other anti-cancer therapy. Bisphosphonates are allowed.
- •Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational not marketed drug within 20 days prior to study entry. Previous trials with antiangiogenic drugs is not allowed.
- •Chronic treatment with steroids unless initiated > 6 months prior to study entry and at low dose (< 20 mg methylprednisolone daily or equivalent)
- •Diagnosis of any second malignancy within the last 5 years, except for adequately treated basal cell or squamous cell skin cancer, or for in situ carcinoma of the cervix uteri.
- •Any of the following within the 12 months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis, or other thromboembolic event.
- •Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥2, atrial fibrillation of any grade, or prolongation of the QTc interval to >450 msec for males or >470 msec for females.
- •Known human immunodeficiency virus (HIV) positivity or acquired immunodeficiency syndrome (AIDS)-related illness.
- •Pregnancy or breastfeeding. Patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of therapy. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) within the 7 days prior to enrollment. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate.
- •Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study.
研究组 & 干预措施
1
Experimental
sutent
干预措施: SU11248 (Drug)
结局指标
主要结局
Progression Free Survival (PFS) at 5 months (= proportion of patients alive and free of progression 5 months after starting therapy in the sunitinib arm (control arm = only for descriptive purpose)
时间窗: 5 months
次要结局
- To compare other measures of antitumor efficacy in both treatment arms of the study(1y)
- To evaluate the safety and tolerability of SU011248(1y)
- To explore the correlations of potential biomarkers with clinical outcomes(1y)
- SU11248 treatment at the time progression after taxane chemotherapy.(1y)
- To confirm efficacy of SU11248 in patients of the control group, who receive delayed(1y)
研究者
prof. dr. Hans Wildiers
adjunct head of clinic
Universitaire Ziekenhuizen KU Leuven
研究点 (13)
Loading locations...
相似试验
终止
2 期
Efficacy of SU 011248 in Head And Neck CarcinomaRecurrent DiseaseSquamous Cell Head and Neck CarcinomaPalliative TreatmentNCT00408252Cliniques universitaires Saint-Luc- Université Catholique de Louvain54
撤回
2 期
Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.Solid TumorCancerOvarian CancerNCT00753740NewLink Genetics Corporation
已完成
1 期
Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic AdenocarcinomaAdvanced Pancreatic CancerMetastatic Pancreatic CancerPancreatic AdenocarcinomaNCT01764477Prism Pharma Co., Ltd.20
Unknown
2 期
Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract CancerTransitional Cell Cancer of the Renal Pelvis and UreterUrethral CancerBladder CancerNCT01118039Hospital del Mar41
已完成
2 期
SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and NeckCarcinoma of Unknown PrimaryHead and Neck CancerNon-melanomatous Skin CancerNCT00006361Memorial Sloan Kettering Cancer Center